{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:06:28Z","timestamp":1789373188064,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Janssen Global Services LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.msard.2026.107403","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:34:16Z","timestamp":1784676856000},"page":"107403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years"],"prefix":"10.1016","volume":"114","author":[{"given":"Tomas","family":"Olsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Hohlfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Sprenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Kubala","family":"Havrdova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Lublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Raghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vaclavkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Pirozek-Lawniczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Burcklen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-5509","authenticated-orcid":false,"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.msard.2026.107403_bib1","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1007\/s00415-022-11169-w","article-title":"Patients with multiple sclerosis: a burden and cost of illness study","volume":"269","author":"Battaglia","year":"2022","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107403_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.107403_bib3","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.107403_bib4","doi-asserted-by":"crossref","first-page":"e762","DOI":"10.1212\/WNL.0000000000200606","article-title":"Long-term treatment with Ponesimod in relapsing-remitting multiple sclerosis: results from randomized phase 2b core and extension studies","volume":"99","author":"Freedman","year":"2022","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.msard.2026.107403_bib5","first-page":"A68","article-title":"Disease activity after short-term interruption of ponesimod versus teriflunomide in relapsing multiple sclerosis patients","volume":"94","author":"Gabriela-Loredana","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.msard.2026.107403_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037297","article-title":"Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment","volume":"103","author":"Haki","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.msard.2026.107403_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211063032","article-title":"The need for a strategic therapeutic approach: multiple sclerosis in check","volume":"13","author":"Inojosa","year":"2022","journal-title":"Ther. Adv. Chronic. Dis."},{"issue":"6","key":"10.1016\/j.msard.2026.107403_bib8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1089\/vim.2023.0035","article-title":"Effect of disease-modifying therapies on COVID-19 vaccination efficacy in multiple sclerosis patients: a comprehensive review","volume":"36","author":"Jamali","year":"2023","journal-title":"Viral. Immunol."},{"issue":"11","key":"10.1016\/j.msard.2026.107403_bib9","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1474-4422(16)30192-2","article-title":"Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"15","author":"Kappos","year":"2016","journal-title":"Lancet Neurol."},{"issue":"10127","key":"10.1016\/j.msard.2026.107403_bib10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.msard.2026.107403_bib11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMa Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107403_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2026.107403_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/WCO.0000000000001262","article-title":"Understanding multiple sclerosis as a disease spectrum: above and below the clinical threshold","volume":"37","author":"Krieger","year":"2024","journal-title":"Curr. Opin. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.107403_bib14","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s40262-023-01308-5","article-title":"Clinical pharmacokinetics of Ponesimod, a selective S1P1 receptor modulator, in the treatment of multiple sclerosis","volume":"62","author":"Kruger","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.msard.2026.107403_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107403_bib16","article-title":"Autoreactive lymphocytes in multiple sclerosis: pathogenesis and treatment target","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2026.107403_bib17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2026.107403_bib18","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA, J. Am. Med. Assoc."},{"issue":"11","key":"10.1016\/j.msard.2026.107403_bib19","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/jnnp-2013-307282","article-title":"Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial","volume":"85","author":"Olsson","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2026.107403_bib20","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107403_bib21","article-title":"Multiple sclerosis: emerging epidemiological trends and redefining the clinical course","volume":"44","author":"Portaccio","year":"2024","journal-title":"Lancet Reg. Health - Eur."},{"issue":"2","key":"10.1016\/j.msard.2026.107403_bib22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2026.107403_bib23","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s10072-021-05049-w","article-title":"Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis","volume":"42","author":"Tong","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107403_bib24","series-title":"Presented at the 38th ECTRIMS Congress, October 26-28, 2022","article-title":"P381. COVID-19 antibody response by vaccine type and lymphocyte count in RMS patients on ponesimod: results from phase 2 long-term extension study AC-058B202","author":"Wong","year":"2022"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:07:02Z","timestamp":1789369622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826004384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":24,"alternative-id":["S2211034826004384"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107403","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107403"}}